lowering drug that blocks intestinal cholesterol uptake by inhibiting the luminal cholesterol transporter Niemann-Pick C1-like 1 protein (NPC1L1), caused major increases in intestinal nuclear SREBP-2 and HMG-CoA Reductase (HMGR), the enzyme that catalyzes the ratedetermining step of the sterol biosynthetic pathway (9) . The activation of SREBP-2 results in a compensatory increase in cholesterol synthesis (10) , which may blunt the cholesterol-lowering effect of ezetimibe. Consistent with this hypothesis is the clinical observation that the action of ezetimibe is enhanced when the drug is given with a statin, which partially blocks the compensatory increase in cholesterol synthesis (11) . Statins also lead to increased nuclear SREBP-2 (12) and HMGR (13) , which also tend to limit effectiveness of these drugs. These observations point to the possible utility of an intestine-specific inhibitor of SREBP-2 processing, which would prevent the compensatory increases that occur with ezetimibe and with statins.
To test this hypothesis, it was necessary to first determine whether Scap and Insig mediate normal processing and feedback inhibition of SREBPs in the intestine as they do in the liver and cultured cells. To answer these questions, we first disrupted Insig-1 and Insig-2 in intestinal epithelium. We observed significant increases in the amount of intestinal nuclear SREBPs and cholesterol synthesis, such that synthesis in the intestine exceeded that in liver on an organ-by-organ basis (14) . Similar results were found when truncated SREBP-2 was expressed in intestinal epithelia (15) . These results indicated that Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine, and suggested that Scap, the binding partner for Insig, also likely plays a role in SREBP processing in the intestine.
In the current studies, we explore the in vivo role of Scap in intestine by generating and characterizing a line of mice with tamoxifen-inducible, intestine-specific deletion of Scap. Our data indicate that Scap-mediated cholesterol synthesis in rapidly proliferating intestinal crypts is required to maintain the integrity of the intestine.
by guest, on September 21, 2017 www.jlr.org Blood Collection and Cytokine Measurements -Mice were euthanized with isoflurane, blood was obtained from the inferior vena cava in EDTA-coated tubes, and plasma was separated and stored at -80°C; metabolic analytes were measured as described previously (7 Crypt Isolation and Culture -Crypt isolation and culture followed closely the protocol developed by Hans Clevers (21) . In brief, small intestines were removed, cut open longitudinally and placed in a 50 ml conical tube containing 30 ml ice cold buffer consisting of PBS with 10 mM EDTA. Intestines were incubated on ice for a total of 45 min with intermittent shaking, decanting, and replacement of buffer to wash away villus elements. Semi-purified crypts were then collected over 30 minutes with intermittent shaking, after which intestinal remnants were removed, and the crypt-containing supernatant was passed serially through cell strainers (100 µm mesh, followed by 70 µm mesh twice) to isolate crypts from larger villus debris. 
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Organoid Treatment and Molecular Analysis -Medium was changed every 1 to 3 days depending upon crypt growth. Media additions were performed as described in the figure For time-lapse microscopy, brightfield images of organoids were captured using a was nearly maximal at day 2.5 ( Fig. 1A) , while intestinal morphology remained normal (Fig. S2 ).
Results
Inducible deletion of Scap in intestinal mucosa
As expected, ligand activation of Cre-ER T2 in Vil-Scap ─ mice did not alter Scap mRNA in the liver, whereas Scap mRNA was reduced by 85% to 92% in segments of large and small intestine compared to Scap flox controls (Fig. 1B) . We subsequently focused on the small intestine rather than the colon since the histological changes at day 4 were much more pronounced in the small intestine than in the colon ( Fig. 3 and Fig. S2 ).
Intestinal Scap disruption provokes a severe enteropathy
The Vil-Scap ─ mice were normal in appearance and behavior for day 0 through day 3. On day 4 after tamoxifen initiation, they became moribund and were euthanized. Every Vil-Scap Taken together, the findings of Fig. 1 -3 demonstrate that Villin-Cre-ER T2 -mediated recombination nearly ablates Scap expression in intestinal mucosa by day 2.5 after ligand administration, and this loss is followed on day 4 by an acute, severe enteropathy characterized by loose stools, weight loss, and sepsis. Inasmuch as the primary function of Scap is to mediate the proteolytic processing of SREBPs in order to drive cholesterol and fatty acid synthesis, we then asked whether the loss of Scap in the intestinal mucosa is associated with reductions in intestinal SREBP proteolysis and lipid synthesis, and whether these reductions occur prior to the onset of overt intestinal injury at day 4.
Intestinal Scap required for SREBP-mediated mucosal lipid synthesis
In Fig. 4 we measured proteolytic processing of SREBPs and the expression of genes required for the synthesis of fatty acids and cholesterol whose transcription is stimulated by SREBPs. Total RNA, membrane fractions, and nuclear extracts of IECs were prepared from To test the whether the loss of Scap and nuclear SREBPs affect intestinal lipid synthesis in vivo, we measured the incorporation of intraperitoneally-injected 3 H-labeled water into digitonin-precipitable sterols and fatty acids in Scap flox and Vil-Scap ─ mice at day 2.5. In the VilScap ─ mice, sterol synthesis was decreased by 37% and 54% in proximal and distal small intestine, respectively (Fig. 5A) . In contrast, fatty acid synthesis was reduced only in the distal small intestine (Fig. 5B) . These data concur with the prior findings that SREBP-2 is more abundant in the ileum than in the proximal small intestine (9, 30 Crypt units were isolated, embedded in matrigel, and grown in basic organoid medium for 4 days, after which 4-hydroxytamoxifen (4-OHT), sodium oleate, and cholesterol complexed to methyl-β-cyclodextrin (MβCD-cholesterol) were added to the culture media as indicated.
Organoids were then grown until the 7 th day after isolation and photographed (Fig. 6A) . Cell viability was measured by ATP bioluminescence assay (35) , in which luciferin is oxidized in an ATP-dependent fashion by firefly luciferase to produce luminescence ( oleate ( Fig. 6A panel 8 ). In cells that received cholesterol plus oleate, 4-OHT caused no decrease in ATP (Fig. 6B) . Oleate alone did not rescue the cells (Fig. 6A panel 7) . Cholesterol alone preserved ATP levels, but the organoids had an abnormal appearance lacking budding protrusions (Fig. 6A panel 6) . Preliminary experiments were also performed to assess whether 4-OHT and we detected no precursor or nuclear forms of SREBPs. We were also unable to detect calnexin, a cellular housekeeping protein, consistent with the disappearance of viable cells. In the presence of cholesterol plus oleate on day 3 we found normal levels of calnexin. Nuclear SREBP-1 was reduced but detectable. Nuclear SREBP-2 was absent, again consistent with the cholesterol-mediated inhibition of SREBP processing. biosynthetic rates to maintain membrane production for cell proliferation (43) . In mice and humans, the surface area of the intestine is 10 to 100-fold greater than that of the skin, and these intestinal mucosal cells turn over every 3-5 days (44, 45) . Prior to the current studies, it was unclear whether SREBPs are needed to drive lipid production or whether lipids absorbed from the intestinal lumen would be sufficient to maintain cell growth and maturation. Here, we show that Scap is required for the maintenance of the intestinal mucosa and that its essential function in this context is to support de novo sterol synthesis in intestinal crypts by promoting SREBP proteolysis. Indeed, the data of Fig. 8 shows that Scap-deficient intestinal crypts survive only when the end product of SREBP action, namely cholesterol, accumulates to levels at which it suppresses SREBP proteolysis.
These data do not answer whether Scap and SREBPs coordinate sterol synthesis and sterol absorption in the intestine. Inasmuch as NPC1L1 expression is intact at day 2.5 ( Fig. 4A) , sterol absorption in villus enterocytes of the Vil-Scap ─ mice is likely intact until this time-point; however, the acuity with which Vil-Scap ─ mice decline from day 2.5 to day 4 precludes our ability to accurately measure sterol absorption in this model.
In addition to the current experiments with intestine-specific Villin-Cre-ER T2 , we performed other experiments in which we disrupted Scap using the ubiquitously expressed UbcCre-ER T2 (46) . The results were nearly identical (Fig. S4) . Tamoxifen-dosed Scap flox/flox ;Ubc-Cre-ER T2 transgenic mice exhibited non-recoverable weight loss, loose stools, and intestinal epithelial destruction over a five-day period, suggesting that the intestinal mucosa is particularly sensitive to perturbation of Scap.
In contrast to the intestine, the liver is able to tolerate loss of Scap. In liver-specific Scap knockouts, liver size and histology is normal (6, 7), suggesting that Scap may not be required for maintenance of organs that have a slower cellular proliferation rate under normal circumstances.
Whether IECs was separately isolated; equal amounts of RNA from each mouse were pooled and subjected to QPCR. Each value represents the mean ± SEM of data from 6 Vil-Scap -mice relative to that of (B) were isolated and subjected to scintillation counting. Intestinal crypts from a Vil-Scap -mouse were isolated, matrigel-embedded, and grown for 4 days, when lipids and 4-OHT were added as described in 
